SEC Form 4 · accession 0001796960-26-000018
INSMED Inc · INSM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Martina Flammer M.D.
Officer — Chief Medical Officer
Period of report
Jul 6, 2026
Accepted (ET)
Jul 8, 2026 · 4:03 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001104506
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 6, 2026 | M | 7,945 | $29.13 | A | 68,431 | D | |
| Common Stock | Jul 6, 2026 | M | 4,357 | $19.74 | A | 72,788 | D | |
| Common StockF2 | Jul 6, 2026 | S | 4,854 | $109.02 | D | 67,934 | D | |
| Common StockF3 | Jul 6, 2026 | S | 7,448 | $110.60 | D | 60,486 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F4 | $29.13 | Jul 6, 2026 | M | 7,945 | D | — | Jan 4, 2034 | Common Stock | 7,945 | 23,835 | D |
| Stock Option (right to buy)F4 | $19.74 | Jul 6, 2026 | M | 4,357 | D | — | Jan 5, 2033 | Common Stock | 4,357 | 4,358 | D |
Explanation of responses
- F1This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
- F2This is the weighted average sales price representing 4,854 shares sold at prices ranging from $108.90 to $109.58 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
- F3This is the weighted average sales price representing 7,448 shares sold at prices ranging from $110.36 to $110.71 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
- F4The options become exercisable based on the following vesting schedule: 25% vest on the first anniversary of the grant date and an additional 12.5% vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant.